Monoclonal antibodies against TNF-α or TNF-α soluble receptors are among the most efficient biological DMARDs (disease-modifying antirheumatic drugs) available for the chronic treatment of rheumatoid arthritis (RA) and other chronic inflammatory diseases. The gene discussed is TNF; the disease is rheumatoid arthritis.